SEC Comment Letter for OptimizeRx Corp (OPRX) (CIK 0001448431) (OPRX) — Nov 19, 2018
OptimizeRx Corp (OPRX) (CIK 0001448431)
Date: Nov. 19, 2018 · CIK: 0001448431 · Accession: 0000000000-18-035742
AI Filing Summary & Sentiment
File numbers found in text: 333-228357
Letter
November 19, 2018 Doug Baker Chief Financial Officer OptimizeRx Corporation 400 Water Street, Suite 200 Rochester, MI 48307 Re:OptimizeRx Corp Registration Statement on Form S-3 Filed November 13, 2018 File No. 333-228357 Dear Mr. Baker: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rule 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Mitchell Austin, Staff Attorney, at (202) 551-3574 or, in his absence, Jan Woo, Legal Branch Chief, at (202) 551-3453 with any questions. Sincerely, Division of Corporation Finance Office of Information Technologies and Services cc: Scott Doney, Esq.
Show Raw Text
November 19, 2018
Doug Baker
Chief Financial Officer
OptimizeRx Corporation
400 Water Street, Suite 200
Rochester, MI 48307
Re:OptimizeRx Corp
Registration Statement on Form S-3
Filed November 13, 2018
File No. 333-228357
Dear Mr. Baker:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rule 461 regarding requests for acceleration. We remind you that the
company and its management are responsible for the accuracy and adequacy of their disclosures,
notwithstanding any review, comments, action or absence of action by the staff.
Please contact Mitchell Austin, Staff Attorney, at (202) 551-3574 or, in his absence, Jan
Woo, Legal Branch Chief, at (202) 551-3453 with any questions.
Sincerely,
Division of Corporation Finance
Office of Information Technologies
and Services
cc: Scott Doney, Esq.